{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T18:39:14Z","timestamp":1785609554059,"version":"3.56.0"},"reference-count":119,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["febs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The FEBS Journal"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>\n                    The therapeutic landscape of acute myeloid leukaemia (AML) has evolved beyond the classic \u20187\u2009+\u20093\u2019\/DA regimen, through the approval and incorporation of targeted treatments in both front\u2010line and relapsed\/refractory settings. Indeed, the use of selective BCL\u20102 antagonists (e.g. venetoclax) and FLT3 inhibitors (e.g. midostaurin, gilteritinib) which target specific molecular characteristics of leukaemic cells, has enhanced outcomes and survival rates. Arguably one of the most exciting advancements has been the clinical development of menin inhibitors for the treatment of patients harbouring specific genetic aberrations. These abnormalities include rearrangements of the lysine methyltransferase 2A (\n                    <jats:italic>KMT2A<\/jats:italic>\n                    ) gene, and they occur in approximately one fifth of childhood\/paediatric (i.e. infant, adolescent and young adult) AML patients. Spurred on by the recent FDA approval of revumenib, menin inhibitors hold the potential to further shift the treatment paradigm for this patient population. Here, we aim to provide a comprehensive overview of the pathogenesis of\n                    <jats:italic>KMT2A<\/jats:italic>\n                    rearrangements, with a focus on KMT2A fusion genes and proteins within paediatric AML patients. Additionally, we summarise the challenges arising from resistance to menin inhibitors, and we touch on the potential of combination therapies to expand the efficacy of menin inhibition and mitigate some of the resistance mechanisms employed by leukaemic clones.\n                  <\/jats:p>","DOI":"10.1111\/febs.70460","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T08:57:14Z","timestamp":1771405034000},"page":"2159-2177","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current perspectives on\n                    <scp>KMT2A<\/scp>\n                    fusion proteins and menin inhibition in paediatric acute myeloid leukaemia"],"prefix":"10.1111","volume":"293","author":[{"given":"Lydia Elaine","family":"Roets","sequence":"first","affiliation":[{"name":"Johnston Cancer Research Centre, Queen's University Belfast  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Greenfield","sequence":"additional","affiliation":[{"name":"Johnston Cancer Research Centre, Queen's University Belfast  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6463-5430","authenticated-orcid":false,"given":"Katrina Mairead","family":"Lappin","sequence":"additional","affiliation":[{"name":"Johnston Cancer Research Centre, Queen's University Belfast  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12899"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026232"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.04.005"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13613"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071963"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4439"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.8997"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02120"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2007.05.019"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00816-X"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2004.08.005"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2008.12.029"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206438"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2010.05.005"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.05.016"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02261-3"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1534-5807(04)00061-9"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.06.010"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.174"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.11.005"},{"key":"e_1_2_10_23_1","article-title":"Updates in KMT2A gene rearrangement in pediatric acute lymphoblastic leukemia","volume":"11","author":"G\u00f3recki M","year":"2023","journal-title":"Biomedicine"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2024.102191"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011771"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2022.02.013"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000539"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000249"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208699"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134056"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6514"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155161"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01877-1"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12250"},{"key":"e_1_2_10_35_1","first-page":"601","article-title":"An alternative splice process renders the MLL protein either into a transcriptional activator or repressor","volume":"68","author":"R\u00f6ssler T","year":"2013","journal-title":"Pharmazie"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.423855"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-362079"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.06.013"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-215152"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.6321"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2016.36.2.85"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01983-3"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2013.05.005"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5311.404"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/6.7.1177"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/bies.201200007"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.09.025"},{"key":"e_1_2_10_49_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/d41573-024-00198-x","article-title":"FDA approves first menin inhibitor, for acute leukaemia","volume":"24","author":"Mullard A","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-429274"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.02.016"},{"key":"e_1_2_10_52_1","first-page":"1682","article-title":"Disruption of the menin\u2010MLL interaction triggers menin protein degradation via ubiquitin\u2010proteasome pathway","volume":"9","author":"Wu Y","year":"2019","journal-title":"Am J Cancer Res"},{"key":"e_1_2_10_53_1","first-page":"258","article-title":"Targeting Menin disrupts the KMT2A\/B and polycomb balance to paradoxically activate bivalent genes","volume":"25","author":"Sparbier CE","year":"2023","journal-title":"Nat Cell Biol"},{"key":"e_1_2_10_54_1","first-page":"1278","article-title":"Bleximenib, the novel menin\u2010KMT2A inhibitor JNJ\u201075276617, impairs long\u2010term proliferation and immune evasion in acute myeloid leukemia","volume":"110","author":"Hogeling SM","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01309-y"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02368-7"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05755-9"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107777"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023644"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0416"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180967"},{"key":"e_1_2_10_62_1","doi-asserted-by":"crossref","unstructured":"MahdaviL GoodrowH AlikaramiF LenardA RiedelSS LibbrechtC BowserI TasianSK FalkensteinCD ManningBet\u00a0al. (2024)Upfront menin\u2010inhibitor resistance in multiply pretreated Leukemias.bioRxiv. 2023.03.16.532874.","DOI":"10.1101\/2023.03.16.532874"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0926"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105381"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022480"},{"key":"e_1_2_10_66_1","unstructured":"HertleinEA\u2010A LermaJ FurbyC LongM JohnstoneM OrryA LamP AbagyanR KhvatA SavchukNet\u00a0al. (2024)The novel menin inhibitor ZE63\u20100302 has an impressive safety profile and unique chemistry that suggests improved efficacy against resistance mutations. Paper Presented at The EHA2024: Madrid Spain."},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02333-4"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02244-4"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04180-1"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185561"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13070227"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.6"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0560"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00786-y"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.773"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm401868d"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01305"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00071"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129126"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01707-w"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.11.001"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05812-3"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168921"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152050"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02877-y"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198959"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173149"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010201"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-2113"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00386-3"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198218"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199170"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-190475"},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204583"},{"key":"e_1_2_10_95_1","unstructured":"KuraO ed. (2025)Frontline Ziftomenib in NPM1\u2010mutated or KMT2A\u2010rearranged acute myeloid Leukemia in patients not eligible for intensive induction or other therapy."},{"key":"e_1_2_10_96_1","unstructured":"Kura OncologyI ed. (2024)A phase I study investigating the combination of the menin inhibitor Ziftomenib with Venetoclax and Gemtuzumab in pediatric patients with acute myeloid Leukemia."},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00826"},{"key":"e_1_2_10_98_1","unstructured":"ShuklaN TasianSK BreeseE SchaferE DipersioJ IssaGC SilvermanLB StieglitzE PollardJ AssoulineSet\u00a0al. (2024)Safety and activity of Revumenib in combination with Fludarabine\/Cytarabine (FLA) in patients with relapsed\/refractory acute Leukemias. Paper Presented at the EHA2024 Congress: Madrid Spain."},{"key":"e_1_2_10_99_1","unstructured":"ClinicalTrials.gov [NCT05886049]A phase 1b study of menin inhibitor SNDX\u20105613 in combination with Daunorubicin and Cytarabine in newly diagnosed patients with acute myeloid Leukemia and NPM1 mutated\/FLT3 wildtype or MLL\/KMT2A REARRANGED Disease. Registered 1 June 2023."},{"key":"e_1_2_10_100_1","unstructured":"SyndaxP ed. (2023)A phase 1 study of Revumenib Azacitidine and Venetoclax in pediatric and young adult patients with refractory or relapsed acute myeloid Leukemia."},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204375"},{"key":"e_1_2_10_102_1","unstructured":"National Cancer I(2024)A phase I Study of SNDX 5613 (Revumenib) as post\u2010transplant maintenance after allogeneic hematopoietic cell transplant in patients with KMT2A\u2010rearranged or NPM1\u2010mutated acute Leukemia."},{"key":"e_1_2_10_103_1","unstructured":"ZeidnerJW LinTL CurranE KoenigK StockW OdenikeO MadanatY SwordsR BaerM SteinEet\u00a0al. (2025)Azacitidine Venetoclax and Revumenib for newly diagnosed older adults with acute myeloid Leukemia (AML) and NPM1 mutation OR KMT2A rearrangement: updated results from the beat AML consortium. Paper presented at the EHA2025: Madrid Spain."},{"key":"e_1_2_10_104_1","unstructured":"ClinicalTrials.gov [NCT06222580]Safety and efficacy of dual menin and FLT3 inhibition in patients with Relapsed\/Refractory FLT3\u2010 mutated acute myeloid leukemia containing a concurrent MLL\u2010rearrangement or NPM1 mutation: A phase I (Ph I) study of SNDX\u20105613 + Gilteritinib. Registered 16 January 2024."},{"key":"e_1_2_10_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-172422"},{"key":"e_1_2_10_106_1","unstructured":"ClinicalTrials.gov [NCT06852222]A phase 3 randomized double\u2010blind placebo\u2010controlled study of Bleximenib Venetoclax and Azacitidine for the treatment of participants with newly diagnosed acute myeloid leukemia harboring KMT2A rearrangements or NPM1 mutations who are ineligible for intensive chemotherapy. Registered 25 February 2025."},{"key":"e_1_2_10_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207072"},{"key":"e_1_2_10_108_1","unstructured":"WeiAH GarciazS AldossI Pi\u00e9rolaAA AllredA DominguezJMA BarreyroA BoriesP DaskalakisN PortaMGDet\u00a0al. (2025)RP2D determination of bleximenib in combination with VEN + AZA: phase 1B study in ND & R\/R AML with KMT2A\/NPM1 alterations. Paper Presented at the EHA2025: Madrid Spain."},{"key":"e_1_2_10_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194827"},{"key":"e_1_2_10_110_1","unstructured":"ClinicalTrials.gov [NCT04752163]An open\u2010label phase 1\/2 multi\u2010arm study of DS\u20101594b as a single\u2010agent and in combination with Azacitidine and Venetoclax or mini\u2010HCVD for the treatment of patients with acute myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL). Registered 8 February 2021."},{"key":"e_1_2_10_111_1","unstructured":"ClinicalTrials.gov [NCT06746519] A phase I\/II multicenter open label clinical study evaluating the safety pharmacokinetics and efficacy of the combination of the menin inhibitor BN104 for the treatment of patients with acute myeloid leukemia. Registered 19 December 2024."},{"key":"e_1_2_10_112_1","unstructured":"ClinicalTrials.gov [NCT06780124] An exploratory randomized double\u2010blind placebo\u2010controlled first\u2010in\u2010human study of the safety tolerability pharmacokinetics and pharmacodynamics of single and multiple ascending doses of ZE63\u20100302 in healthy volunteers. Registered 16 January 2025."},{"key":"e_1_2_10_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021105"},{"key":"e_1_2_10_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19591"},{"key":"e_1_2_10_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00826-6"},{"key":"e_1_2_10_116_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282160"},{"key":"e_1_2_10_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022832"},{"key":"e_1_2_10_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.327"},{"key":"e_1_2_10_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57544-9"},{"key":"e_1_2_10_120_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00603-3"}],"container-title":["The FEBS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/febs.70460","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/febs.70460","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/febs.70460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:53:40Z","timestamp":1776232420000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1111\/febs.70460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":119,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/febs.70460"],"URL":"https:\/\/doi.org\/10.1111\/febs.70460","archive":["Portico"],"relation":{},"ISSN":["1742-464X","1742-4658"],"issn-type":[{"value":"1742-464X","type":"print"},{"value":"1742-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"2025-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}